A new analysis from TAILORx, the largest ever breast cancer treatment trial, is published today in JAMA Oncology. It reveals the clinical outcomes with chemotherapy in a subset of 1,389 women with a high Recurrence Score ...
Sep 30, 2019
0
3
The PARP inhibitor olaparib (Lynparza) in combination with the chemotherapeutic agent temozolomide (Temodar) showed clinical efficacy in patients with relapsed small cell lung cancer (SCLC), according to results from a phase ...
Aug 16, 2019
0
2
Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent ...
Jun 04, 2019
0
1
Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder. But which type of chemotherapy leads to the best outcomes in terms of complete response rates ...
Aug 31, 2018
0
14
Survival results for the CALGB 80303 Trial presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 demonstrate that esophageal cancer patients shown by PET scan to be non-responders to induction ...
Jun 03, 2018
0
4
In a federally funded, randomized phase III clinical trial performed by the Children's Oncology Group (COG), 90 percent of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic ...
May 17, 2018
0
3
For patients with colorectal cancer that has metastasized to the liver, having a primary tumour on the left side, as opposed to the right side of the colon, is known to be a significant advantage in terms of treatment response.
Jul 01, 2017
0
1
After surgery for lymph-node positive colon cancer (stage III), some patients may only need half of the long-standing standard course of chemotherapy. In an analysis of six clinical trials with over 12,800 patients, 3 months ...
Jun 05, 2017
0
1
Neoadjuvant chemotherapy with an anthracycline plus ifosfamide was associated with significant survival gains in patients with soft tissue sarcoma of the trunk or extremities who are at high-risk of recurrence, in an interim ...
Oct 10, 2016
0
2
Osteosarcoma patients with tumors that haven't responded well to the standard chemotherapy regimen have unimproved outcomes and more side effects when given two additional drugs, a large international trial has found.
Aug 26, 2016
0
0
